Ignite Creation Date:
2024-05-06 @ 12:18 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01541306
Status:
COMPLETED
Last Update Posted:
2015-04-14
First Post:
2012-02-13
Brief Title:
C-Type Natriuretic Peptide and Achondroplasia
Sponsor:
Nemours Childrens Clinic
Organization:
Nemours Childrens Clinic
Study Overview
Official Title:
C-Type Natriuretic Peptide and Achondroplasia
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Achondroplasia and hypochondroplasia are the most common forms of dwarfism Recent studies have shown that a small hormone called C-type natriuretic peptide CNP is an important regulator of linear growth The investigators believe that genetic abnormality that causes achondroplasia and hypochondroplasia also disrupts CNP signaling which may contribute to the growth problem The investigators propose to look at levels of this and other closely related hormones in children and adults with achondroplasia or hypochondroplasia to see if they are different from levels in healthy people The investigators hypothesis is that CNP levels are elevated in children with achondroplasia or hypochondroplasia compared the healthy population Another hypothesis is that CNP levels are not elevated in adults with achondroplasia or hypochondroplasia since adults have no growth-plate cartilage By studying the potential role of the CNP system in achondroplasia and hypochondroplasia not only will the investigators provide further insight into the pathophysiology of these common syndromes the investigators will also provide greater insight into the regulation of normal linear growth
Detailed Description:
Achondroplasia is the most common form of dwarfism and is characterized by short limbs with the thighs and upper arms being the most affected Achondroplasia is also associated with a narrowing of the foramen magnum and spinal stenosis Hypochondroplasia is a related but less severe form of dwarfism that does not have the neurologic problems Achondroplasia and hypochondroplasia are caused by mutations in the fibroblast growth factor receptor-3 FGFR-3 gene that causes constitutive activation of the receptor FGFR-3 signals primarily through the MAP kinase pathway which is overactivated in growth plate chondrocytes in achondroplasia C-type natriuretic peptide CNP is a hormone that is produced and acts in the growth plate as a potent positive regulator of linear growth CNP signals through natriuretic peptide receptor-B NPR-B generating cGMP Studies in mice show that activation of the MAP kinase pathway inhibits signaling through NPR-B Hence the achondroplasia phenotype may be due in part to inhibition of CNP signaling Conversely CNP intracellular signaling inhibits the MAP kinase pathway and CNP analogs are being studied as a potential specific therapy for achondroplasia The objective of this project is to define the state of the CNP system in children and adults with achondroplasia or hypochondroplasia Our hypotheses are 1 blood levels of CNP and its aminoterminal propeptide NTproCNP are elevated and blood levels of cGMP are reduced in children with achondroplasia or hypochondroplasia due to inhibition of NPR-B 2 CNP and NTproCNP levels are normal in adults with achondroplasia and hypochondroplasia due to their lack of growth plate cartilage and 3 as in healthy children NTproCNP levels predict height velocity in children with achondroplasia or hypochondroplasia These hypotheses will be addressed with two specific aims Specific aim 1 is to determine plasma levels of CNP NTproCNP and cGMP in children and adults with achondroplasia or hypochondroplasia Specific aim 2 is to determine if NTproCNP levels correlate with height velocity in children with achondroplasia or hypochondroplasia
The study is an observational cross-sectionalpartially longitudinal study of children and adults with achondroplasia or hypochondroplasia Children will be seen as part of routine clinic visits Children seen more than once during the study period will provide longitudinal data Adult subjects with achondroplasia or hypochondroplasia will be studied a single time Data collected will include anthropometrics information on neurologic complications of achondroplasia and blood levels of CNP NTproCNP and cGMP We anticipate 100 subjects will be recruited with about 20 being studied as many as three times during the course of the study
By studying the potential role of the CNP system in achondroplasia and hypochondroplasia not only will we provide further insight into the pathophysiology of these common syndromes we will also provide greater insight into the regulation of normal linear growth
The study is an observational cross-sectionalpartially longitudinal study of children and adults with achondroplasia or hypochondroplasia Children will be seen as part of routine clinic visits Children seen more than once during the study period will provide longitudinal data Adult subjects with achondroplasia or hypochondroplasia will be studied a single time Data collected will include anthropometrics information on neurologic complications of achondroplasia and blood levels of CNP NTproCNP and cGMP We anticipate 100 subjects will be recruited with about 20 being studied as many as three times during the course of the study
By studying the potential role of the CNP system in achondroplasia and hypochondroplasia not only will we provide further insight into the pathophysiology of these common syndromes we will also provide greater insight into the regulation of normal linear growth
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None